🟢 Corcept Therapeutics is trading 4.8% up today after raising its full-year revenue guidance and reporting strong earnings

Corcept Therapeutics is trading at $119.99 (+4.80%) in pre-market following its July 29 earnings report, which highlighted strong launch momentum for Lifyorli and a significantly improved 2026 outlook.

• The company raised its full-year revenue guidance to a range of $1.1–$1.2 billion, a key driver for the continued upward momentum in the August 3 session.
• The upbeat earnings and guidance reset remain the primary catalysts for the stock, with additional support coming from slightly higher U.S. futures.